Multiple Sclerosis Drugs - Jordan

Jordan

The Multiple Sclerosis Drugs market in Jordan is anticipated to witness a substantial growth in revenue, with projections indicating a reaching of US$6.10m in 2024.
It is expected that the market will continue to expand steadily, displaying an annual growth rate (CAGR 2024-2029) of 0.93%.
This positive trend is estimated to lead to a significant increase in the market volume, reaching US$6.39m by 2029.
When considering the global landscape, it is noteworthy that United States is anticipated to generate the highest revenue in the market.
In 2024, United States is projected to contribute a substantial amount of US$11,770.00m to the overall revenue.
The introduction of innovative multiple sclerosis drugs in Jordan has significantly improved patient outcomes and expanded treatment options.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis (MS) drugs in Jordan has been on the rise in recent years.

Customer preferences: Patients suffering from MS in Jordan are showing a growing preference for disease-modifying therapies (DMTs) which slow down the progression of the disease and reduce the frequency and severity of relapses. This is due to the fact that DMTs have been proven to be more effective in treating MS than other forms of medication.

Trends in the market: The market for MS drugs in Jordan has been growing steadily due to the increasing prevalence of the disease in the country. Additionally, the government has been taking measures to improve the healthcare system in the country, which has resulted in better access to healthcare for patients suffering from MS. This has led to an increase in the number of patients seeking treatment for the disease, which has in turn driven the demand for MS drugs.

Local special circumstances: One of the major challenges in the MS drugs market in Jordan is the high cost of treatment. Most MS drugs are expensive and not affordable for the majority of the population. This has resulted in a significant number of patients being unable to access the medication they need. Additionally, there is a lack of awareness about the disease among the general population, which has led to delays in diagnosis and treatment.

Underlying macroeconomic factors: The Jordanian economy has been growing steadily in recent years, with a focus on diversification and modernization. This has led to an increase in disposable income and an improvement in the standard of living for many Jordanians. This has had a positive impact on the healthcare sector, with more people seeking medical treatment. Additionally, the government has been taking steps to improve the healthcare system in the country, which has resulted in better access to healthcare for patients suffering from MS.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.